Signos has raised $53M across 2 funding rounds, plus 1 undated round. The latest round valued Signos at $1B post-money, with GV (Google Ventures), Dexcom, Blue Cross Blue Shield on the lead line.
2 funding rounds, the latest highlighted.
Signos was founded in 2016, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $13M raised, led by GV.
A primary round — the company sells new shares to investors it selects. $20M raised, led by GV (Google Ventures), Dexcom, Blue Cross Blue Shield.
No filing has been made.
2 dated rounds, newest first.
GVLEAD
GVLEAD
DexcomLEADBBlue Cross Blue ShieldLEAD
General Catalyst
Accel PartnersThe last valuation is $1B (post-money, May 2026).
Lead investors for each round are in the funding timeline.
The closest healthtech / diabetes peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
